摘要
目的分析miR-155、miR-34a和miR-30a在弥漫大B细胞淋巴瘤（diffuselargeB-celllymphoma，DLBCL）中的表达水平，并探讨其与DLBCL临床病理特征的关系以及在DLBCL发生发展中扮演的角色。方法应用RT-PCR方法检测46例DLBCL中miR-155、miR-34a及miR-30a的表达水平，用间期荧光原位杂交技术分析患者MYC和p53基因的异常情况，用免疫组织化学技术（Envision法）对DLBCL进行CD3、CDl0、CD20、BCL-6、MUM-1标记。根据Hans的分类方法分为生发中心B细胞型（GCB型）和非生发中心B细胞型（non-GCB型）。结果与正常对照组相比，miR-155在DLBCL中显著高表达。miR-155在non-GCB型的表达明显高于GCB型。miR-155在MYC基因重排组表达降低。miR-34a在p53基因丢失组的表达较p53基因正常组显著降低。与BCL-6蛋白阴性表达组相比，miR-30a在BCL-6蛋白阳性组明显低表达。结论miR-155在正常人群与DLBCL以及DLBCL的不同亚型之间表达不同，对DLBCL的诊断分型有一定参考价值。miR-34a对疾病预后判断有一定指导意义。miR-155、miR-34a和miR-30a可能是DLBCL潜在的治疗靶点。
Objective To determine the expressions of miR-155, miR-34a and miR-30a in diffuse large B-cell lymphoma and to explore their potential correlation with clinicopathological characteristics. Methods The expression level of miR-155, miR-34a and miR-30a in 46 DLBCL samples were determined with TaqMan real-time polymerase chain reaction. Interphase fluorescence in situ hybridization （/-FISH） was performed to detect MYC and p53 gene status and immunohistochemistry （Envision method） was used to evaluate the expression of CD3, CD10, CD20, BCL-6 and MUM-1 in DLBCL. The DLBCLs were classified into germinal center B cell-like （GCB） and non-germinal center B cell-like （non-GCB） subtypes according to Hans＇ criteria. Results Compared with normal controls, miR-155 expression level was significantly higher in DLBCL. The expression level of miR-155 in non-GCB type was higher than that in GCB type. It was shown that the patients with MYC rearrangement had lower expression level of miR-155 than the negative controls. Compared with p53 normal group, the expression level of miR-34a was significantly lower in p53 deletion group. It was also shown that the patients with BCL-6 protein positive had lower expression level of miR-30a than the negative group. Conclusion miR-155 expression level is different in normal controls, DLBCL and patients of subtype DLBCL. It therefore has a diagnosis value for DLBCL. miR-34a is of great prognostic significance, miR-155, miR-34a and miR-30a may be potential therapy targets for DLBCL.
出处
《中华医学遗传学杂志》
CAS
CSCD
北大核心
2013年第1期79-83,共5页
Chinese Journal of Medical Genetics
基金
卫生部基金资助项目（WKJ2007-3-001）
